Related Experiment Video

Updated: Jul 20, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Chemokines in multiple myeloma

Rohit Aggarwal1, Irene M Ghobrial, G David Roodman

  • 1Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA 15240, USA.

Experimental Hematology
|September 20, 2006
PubMed
Abstract

Insights

Chemokines and their receptors are key drivers in multiple myeloma progression and bone destruction. Targeting these pathways offers a promising therapeutic strategy for multiple myeloma patients.

Area of Science:

  • Immunology
  • Oncology
  • Bone Biology

Background:

  • Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
  • MM pathogenesis involves complex interactions within the bone marrow microenvironment.
  • Bone destruction is a hallmark complication of multiple myeloma, leading to significant morbidity.

Purpose of the Study:

  • To review the role of chemokines and chemokine receptors in multiple myeloma pathogenesis.
  • To evaluate the therapeutic potential of targeting chemokine pathways in MM.

Main Methods:

  • Review of current scientific literature on chemokines, chemokine receptors, and multiple myeloma.
  • Analysis of the involvement of specific chemokines (MIP-1alpha, MCP-1, IL-8, SDF-1) and their receptors.

Main Results:

  • Chemokines and their receptors are crucial for multiple myeloma cell homing, tumor growth, and bone destruction.
  • Specific chemokines like MIP-1alpha, MCP-1, IL-8, and SDF-1 are implicated in MM progression.
  • These molecules represent viable therapeutic targets for MM treatment.

Conclusions:

  • Inhibiting chemokine pathways can enhance therapeutic responses in multiple myeloma.
  • Chemokine antagonists may overcome the protective effects of the bone marrow microenvironment on MM cells.
  • Targeting chemokines could reduce osteoclast activity, mitigating bone destruction in MM.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...